

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Simcere Pharmaceutical Group Limited

先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

PROPOSED AMENDMENTS TO THE EXISTING ARTICLES OF ASSOCIATION AND ADOPTION OF THE NEW ARTICLES OF ASSOCIATION

This announcement is made by Simcere Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited in relation to the proposed amendments to the existing articles of association of the Company (the “**Existing Articles of Association**”).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company proposes to (a) make the proposed amendments to the Existing Articles of Association (the “**Proposed Amendments**”) in order to (i) align with the Core Shareholder Protection Standards set out in Appendix A1 of the Listing Rules which require, among others, the holding of general meetings which shareholders can attend virtually with the use of technology and cast votes by electronic means; (ii) permit the Company to hold treasury shares aligning with the amended Companies Ordinance (Chapter 622 of the Laws of Hong Kong) in relation to the implementation of the treasury share regime for Hong Kong incorporated listed companies; and (iii) incorporate certain housekeeping amendments; and (b) adopt the new amended and restated articles of association of the Company (the “**New Articles of Association**”).

The Proposed Amendments and the adoption of the New Articles of Association are subject to the approval of the shareholders of the Company by way of a special resolution at the forthcoming annual general meeting of the Company (the “**AGM**”) to be convened and held by the Company. A circular containing, inter alia, details of the Proposed Amendments and the adoption of the New Articles of Association, together with a notice convening the AGM, will be disseminate to the shareholders of the Company electronically in due course.

By order of the Board
Sincere Pharmaceutical Group Limited
Mr. REN Jinsheng
Chairman and Executive Director

Hong Kong, March 25, 2026

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director; Mr. TANG Renhong, Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.